Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Crizotinib Established as First-Line Therapy for ALK-Positive NSCLC

August 4th 2014

As a first-line treatment, crizotinib (Xalkori) improved progression-free survival (PFS) and objective response rate (ORR) compared with standard chemotherapy in patients with advanced ALK-positive non–small cell lung cancer (NSCLC).

Next-Generation ALK Inhibitors Effective in Patients With Brain Metastases

August 2nd 2014

New generations of potent ALK inhibitors have been designed with extensive CNS activity and the ability to overcome acquired resistance mutations.

Dr. Vokes Discusses PARP Inhibitors in Lung Cancer

August 2nd 2014

Everett E. Vokes, MD, Giant of Cancer Care: Lung Cancer, John E. Ultmann Professor Chair, Department of Medicine, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses PARP inhibitors as treatments for patients with lung cancer.

Herbst Tackles Key Questions in Emerging PD-1/PD-L1 Immunotherapy for NSCLC

August 2nd 2014

Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way.

Dr. Papadimitrakopoulou Discusses the Lung-MAP Trial

August 2nd 2014

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the Lung-MAP trial, which uses next-generation sequencing as a screening test rather than screening for one mutation.

Novel EGFR Specific Agents Impress in NSCLC

August 2nd 2014

Third generation EGFR TKIs have demonstrated dramatic benefits for patients with non-small cell lung cancer (NSCLC) and should be considered as a standard second-line option following resistance to frontline therapy

TKIs Combined With Other Drugs May Prove More Effective in NSCLC

August 1st 2014

Tyrosine kinase inhibitors (TKIs) are effective as single agents in EGFR-positive non-small cell lung cancer (NSCLC), but investigators continue to ask questions about how to improve the results of these agents.

Search for Curative Therapies Continues in Lung Cancer

August 1st 2014

Curative strategies for patients with advanced lung cancer remain elusive despite several exciting advancements, according to Paul A. Bunn Jr, MD, and Primo N. Lara Jr, MD, who delivered keynote lectures during the 15th Annual International Lung Cancer Congress.

Dr. Hirsch Discusses the Role of Next-Generation EGFR Inhibitors

August 1st 2014

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.

Experimental Drugs Hit KRAS and Downstream Targets in NSCLC

August 1st 2014

The KRAS mutation in lung cancer is an especially thorny problem, as it is an indicator of a poor prognosis and has not, in the past, been targeted specifically by any medications.

Dr. Ramalingam Discusses the Utility of Tecemotide in NSCLC

August 1st 2014

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the utility of the vaccine tecemotide as treatment for non-small cell lung cancer.

Dr. Bunn Discusses Companion Diagnostic Tests in Lung Cancer

July 31st 2014

Paul A. Bunn, Jr., MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses the pros and cons of having companion diagnostic tests in lung cancer.

CT Screening for Lung Cancer an Important Life-Saving Tool

July 31st 2014

When the US Preventive Services Task Force (USPSTF) recommended last year that asymptomatic, high-risk individuals should receive annual screening for lung cancer with low-dose computed tomography (LDCT), it made a healthy decision for the American population

Dr. Mulshine Discusses New Recommendations for Lung Cancer Screening

July 31st 2014

James L. Mulshine, MD, professor, Associate Provost for Research, Vice President, Rush University Medical Center discusses new USPSTF recommendations for lung cancer screening.

Ambitious Lung-MAP Trial Launched With Five Novel Drugs

July 31st 2014

Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial

Lung Congress to Offer Thorough Review of Latest Research Findings

July 31st 2014

The 15th Annual International Lung Cancer Congress, which began today in Huntington Beach, California and will continue through Saturday, will offer an array of information presented by multidisciplinary experts-in a brand-new format.

Anti-PD-L1 Antibody MEDI4736 Shows Clinical Activity in NSCLC and Is Well Tolerated

July 30th 2014

The anti-PD-L1 antibody MEDI4736 has early and durable activity in patients with non–small cell lung cancer (NSCLC) of both squamous and nonsquamous histology, with higher objective response rates occurring in PD-L1–positive patients, according to results of an ongoing phase I study.

Dr. Pass Discusses Resistance in Mesothelioma

July 29th 2014

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses treatment resistance in mesothelioma.

Promising Findings for Afatinib-Cetuximab Combo in Previously Treated EGFR-Mutant Lung Cancer

July 29th 2014

Results of an early-phase study have shown the combination of afatinib (Gilotrif) and cetuximab (Erbitux) has utility in EGFR-mutant lung cancer patients who have developed resistance to gefitinib (Tarceva) and erlotinib (Iressa).

Dr. Reckamp on MK-2206 for the Treatment of EGFR Wild-Type NSCLC

July 28th 2014

Karen L. Reckamp, MD, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

NEXT PAGE
PREVIOUS PAGE